However, the efficacy of these agents is highly context-dependent, and fully harnessing the power of these promising therapeutics requires detailed understanding of how p53 mutation affects chemoresistance pathways and the tumor intracellular and extracellular environments. This evidence concerns the gene TP53 and neoplasm.